“重大新药创制”重大专项:我国药物创新体系建设与发展的新引擎  

National science and technology major projects for new drug development:a new engine for China's drug innovation system

作　　者：孙宇[1] 米献淼[1] 李鹏燕[2] 徐守军[1] 张立国[1] 张永祥[1] 

机构地区：[1]军事医学科学院科技部,北京100850 [2]军事医学科学院毒物药物研究所,北京100850

出　　处：《中国新药杂志》2013年第8期868-872,共5页Chinese Journal of New Drugs

基　　金："重大新药创制"科技重大专项(2012ZX09301003)

摘　　要：药物创新体系对新药创制发挥重要的支撑和推动作用。长期以来,我国新药研发的主体主要是科研院所,呈多元、分散的模式。加之我国药物创新体系的不完善,成为影响我国新药研发进程的重要制约因素之一。本文对目前我国新药研发的模式进行了分析,并结合"重大新药创制"国家科技重大专项的实施,提出我国未来药物创新体系建设与发展的思路。Drug innovation systems play an important role in supporting and promoting drug innovation. For a long time, China＇s drug innovation has been the responsibility of research institutes and universities, which a- dopt a diverse and dispersed pattern of innovaiton. Besides, the imperfect drug innovation system has become an obstacle to China＇s drug development process. By reviewing China＇s existing mode of drug R＆D systematically, the drug innovation system in the future is proposed in this article.

关 键 词：重大新药创制 国家科技重大专项 国家药物创新体系 新药研发 技术创新主体 

分 类 号：R95[医药卫生—药学]